Icaritin Shows Potent Anti-Leukemia Activity on Chronic Myeloid Leukemia In Vitro and In Vivo by Regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT Signalings. Here, MAPK8 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.